SCHEMBL23896809

SCHEMBL23896809

CC(O)c1ccc(C(=O)O)cc1F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.51
MAPK1 P28482 1/20 0.51
HTT P42858 1/20 0.51
RAB9A P51151 1/20 0.51
ACE2 Q9BYF1 4/20 0.46
GRM1 Q13255 2/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
CYP1A2 P05177 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
TSHR P16473 2/20 0.40
KDM4E B2RXH2 2/20 0.40
HSD17B10 Q99714 1/20 0.40
CA12 O43570 2/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA4 P22748 2/20 0.39
CA6 P23280 2/20 0.39
CA7 P43166 2/20 0.39
CA9 Q16790 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2627846 0.87 ACE2 (0.56) LMNAMAPK1HTTRAB9AACE2
SCHEMBL18285572 0.85 LMNA (0.50) LMNAMAPK1HTTRAB9AACE2
SCHEMBL27822624 0.84 LMNA (0.50) LMNAMAPK1HTTRAB9AACE2
SCHEMBL3649293 0.84 GRM1 (0.51) LMNAMAPK1HTTRAB9AACE2
SCHEMBL12584011 0.84 GRM1 (0.51) LMNAMAPK1HTTRAB9AACE2
SCHEMBL7768437 0.82 ACE2 (0.50) RAB9AACE2GRM1KMT2AMEN1
Hydrochloric Acid SCHEMBL6559020 0.82 GRM1 (0.50) LMNAMAPK1HTTRAB9AACE2
Hydrochloric Acid SCHEMBL20539066 0.82 GRM1 (0.50) LMNAMAPK1HTTRAB9AACE2
Hydrochloric Acid SCHEMBL3654866 0.82 GRM1 (0.50) LMNAMAPK1HTTRAB9AACE2
SCHEMBL12491998 0.81 ACE2 (0.60) LMNAMAPK1HTTRAB9AACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021203014-A1 PYRANO[4,3-B]L NDOLE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-10-07 WO disclosed